Home / Therapies / GLP-1 Agonist Therapy Center

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

Using Semaglutide and Liraglutide To Protect the Kidney?

1 week ago Articles, GLP-1 Agonist Therapy Center, Nephrology

A two-for-one deal: both cardiovascular benefits and renal protection.

Common Diabetes Medication as Treatment for Parkinson’s Disease

2 weeks ago Articles, GLP-1 Agonist Therapy Center, Paid, Type 2 Diabetes

Findings show Parkinson’s disease risk is reduced in patients with type 2 diabetes mellitus (T2DM) after treatment with exenatide.

Glycemic Benefit of Weekly GLP-1 Agonist: Albiglutide

Jan 19, 2021 Articles, Blood Glucose Control, GLP-1 Agonist Therapy Center

Simple add-on therapy can reduce insulin use for patients with type 2 diabetes.

The Efficacy of GLP-1 Agonists in Kidney Transplant Recipients with Type 2 Diabetes

Dec 1, 2020 Articles, GLP-1 Agonist Therapy Center, Type 2 Diabetes

Treatment of diabetes in patients undergoing organ replacement is not often studied.

Using Pens – Keep It In and Hold It Down!

Nov 24, 2020 Disasters Averted, GLP-1 Agonist Therapy Center

Susan received a phone call from her clinician's office recommending that she start using a pen for her insulin. She had also been prescribed a GLP-1 receptor agonist and was to go to the pharmacy to pick them up.
She went and signed up for the long 'discourse' patients receive when they pick up new meds including questions such as whether or not the pharmacist had offered instructions and pages of small print. She, like many of our patients, signed the sheets and went on her own way without ever talking to a pharmacist or asking a question.

Weekly Semaglutide vs. Daily Sitagliptin in T2D Patients

Nov 17, 2020 GLP-1 Agonist Therapy Center, Paid, Type 2 Diabetes

One diabetes drug showed superior results for A1C reduction and weight loss.

The Benefits of Exenatide From the EXSCEL Study

Nov 14, 2020 GLP-1 Agonist Therapy Center, Nephrology

The EXSCEL trial may not have shown that once-weekly exenatide had cardiovascular benefits for patients with diabetes, but did show a benefit in some significant areas.